These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24885546)

  • 1. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
    Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
    Virol J; 2014 May; 11():84. PubMed ID: 24885546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
    Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
    J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
    Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
    Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
    Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
    J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of newcastle disease virus strain D90 on human lung cancer cell line A549.
    Fu F; Zhao M; Yang YJ; Tong GZ; Yang BF; Song C; Li X
    Oncol Res; 2011; 19(7):323-33. PubMed ID: 21936402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NDV-D90 suppresses growth of gastric cancer and cancer-related vascularization.
    Sui H; Wang K; Xie R; Li X; Li K; Bai Y; Wang X; Bai B; Chen D; Li J; Shen B
    Oncotarget; 2017 May; 8(21):34516-34524. PubMed ID: 28388537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells.
    Shan P; Tang B; Xie S; Zhang Z; Fan J; Wei Z; Song C
    J Cell Biochem; 2021 Jan; 122(1):3-15. PubMed ID: 32985706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells.
    Jiang K; Li Y; Zhu Q; Xu J; Wang Y; Deng W; Liu Q; Zhang G; Meng S
    BMC Cancer; 2014 Jul; 14():551. PubMed ID: 25078870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
    He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
    Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
    He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
    J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
    Huang Z; Liu M; Huang Y
    Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rescue of a recombinant Newcastle disease virus expressing the green fluorescent protein].
    Ge JY; Wen ZY; Wang Y; Bao ED; Bu ZG
    Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):547-51. PubMed ID: 17037052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
    Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
    Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expressing foreign genes by Newcastle disease virus for cancer therapy].
    Bai FL; Tian H; Yu QZ; Renl GP; Li DS
    Mol Biol (Mosk); 2015; 49(2):195-204. PubMed ID: 26065249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
    Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
    Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting.
    Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G
    Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.